{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:12:23Z","timestamp":1791331943282,"version":"4.3.1"},"reference-count":107,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2014,7,1]],"date-time":"2014-07-01T00:00:00Z","timestamp":1404172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,3,12]],"date-time":"2014-03-12T00:00:00Z","timestamp":1394582400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"content-domain":{"domain":["transplantationreviews.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation Reviews"],"published-print":{"date-parts":[[2014,7]]},"DOI":"10.1016\/j.trre.2014.03.002","type":"journal-article","created":{"date-parts":[[2014,3,16]],"date-time":"2014-03-16T18:17:00Z","timestamp":1394993820000},"page":"126-133","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":286,"title":["Strategies for the management of adverse events associated with mTOR inhibitors"],"prefix":"10.1016","volume":"28","author":[{"given":"Bruce","family":"Kaplan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasir","family":"Qazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason R.","family":"Wellen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.trre.2014.03.002_bb0005","first-page":"133","article-title":"mTOR inhibitor\/proliferation signal inhibitors: entering or leaving the field?","volume":"23","author":"Rostaing","year":"2010","journal-title":"J Nephrol"},{"key":"10.1016\/j.trre.2014.03.002_bb0010","doi-asserted-by":"crossref","first-page":"4256","DOI":"10.1002\/cncr.25219","article-title":"Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors","volume":"116","author":"Motzer","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.trre.2014.03.002_bb0015","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa066838","article-title":"Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma","volume":"356","author":"Hudes","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trre.2014.03.002_bb0020","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.2174\/138161212800626210","article-title":"Targeting mTOR pathways in human malignancies","volume":"18","author":"Fasolo","year":"2012","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.trre.2014.03.002_bb0025","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.2337\/db09-1324","article-title":"Chronic rapamycin treatment causes glucose intolerance and hyperlipidemia by upregulating hepatic gluconeogenesis and impairing lipid deposition in adipose tissue","volume":"59","author":"Houde","year":"2010","journal-title":"Diabetes"},{"key":"10.1016\/j.trre.2014.03.002_bb0030","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1093\/ndt\/gfq617","article-title":"The podocyte as a direct target of immunosuppressive agents","volume":"26","author":"Sch\u00f6nenberger","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.trre.2014.03.002_bb0035","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1681\/ASN.2011070690","article-title":"Inhibition of MTOR disrupts autophagic flux in podocytes","volume":"23","author":"Cin\u00e0","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.trre.2014.03.002_bb0040","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1097\/01.ASN.0000102469.32182.8C","article-title":"Addition of sirolimus to cyclosporine delays the recovery from delayed graft function but does not affect 1-year graft function","volume":"15","author":"Stallone","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.trre.2014.03.002_bb0045","doi-asserted-by":"crossref","first-page":"E83","DOI":"10.1188\/11.CJON.E83-E89","article-title":"Managing stomatitis in patients treated with Mammalian target of rapamycin inhibitors","volume":"15","author":"Pilotte","year":"2011","journal-title":"Clin J Oncol Nurs"},{"key":"10.1016\/j.trre.2014.03.002_bb0050","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1093\/ndt\/gfp674","article-title":"Anaemia, microcytosis and sirolimus\u2014is iron the missing link?","volume":"25","author":"Sofroniadou","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.trre.2014.03.002_bb0055","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1053\/j.ajkd.2010.10.048","article-title":"Hypertension after kidney transplant","volume":"57","author":"Mangray","year":"2011","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.trre.2014.03.002_bb0060","doi-asserted-by":"crossref","first-page":"e45868","DOI":"10.1371\/journal.pone.0045868","article-title":"Low-dose oral sirolimus and the risk of menstrual-cycle disturbances and ovarian cysts: analysis of the randomized controlled SUISSE ADPKD trial","volume":"7","author":"Braun","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.trre.2014.03.002_bb0065","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1111\/j.1600-6143.2004.00456.x","article-title":"Sirolimus impairs gonadal function in heart transplant recipients","volume":"4","author":"Kaczmarek","year":"2004","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2014.03.002_bb0070","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1097\/TP.0b013e3182551021","article-title":"Wound healing complications and the use of mammalian target of rapamycin inhibitors in kidney transplantation: a critical review of the literature","volume":"94","author":"Nashan","year":"2012","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2014.03.002_bb0075","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1097\/01.TP.0000151630.25127.3A","article-title":"Cutaneous adverse events in renal transplant recipients receiving sirolimus-based therapy","volume":"79","author":"Mah\u00e9","year":"2005","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2014.03.002_bb0080","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/cncr.24696","article-title":"Preliminary characterization of oral lesions associated with inhibitors of mammalian target of rapamycin in cancer patients","volume":"116","author":"Sonis","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.trre.2014.03.002_bb0085","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.urology.2012.09.019","article-title":"Safety of everolimus by treatment duration in patients with advanced renal cell cancer in an expanded access program","volume":"81","author":"van den Eertwegh","year":"2013","journal-title":"Urology"},{"key":"10.1016\/j.trre.2014.03.002_bb0090","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1016\/j.transproceed.2010.07.083","article-title":"Comparative analysis of adverse events requiring suspension of mTOR inhibitors: everolimus versus sirolimus","volume":"42","author":"S\u00e1nchez-Fructuoso","year":"2010","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2014.03.002_bb0095","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/S0140-6736(00)02480-6","article-title":"Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. The Rapamune US Study Group","volume":"356","author":"Kahan","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.trre.2014.03.002_bb0100","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/00007890-200101270-00019","article-title":"A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus\/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts","volume":"71","author":"MacDonald","year":"2001","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2014.03.002_bb0105","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.1111\/j.1600-6143.2012.04212.x","article-title":"Everolimus with reduced tacrolimus improves renal function in de novo liver transplant recipients: a randomized controlled trial","volume":"12","author":"De Simone","year":"2012","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2014.03.002_bb0110","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1111\/j.1432-2277.2012.01465.x","article-title":"Everolimus plus early tacrolimus minimization: a phase III, randomized, open-label, multicentre trial in renal transplantation","volume":"25","author":"Langer","year":"2012","journal-title":"Transpl Int"},{"key":"10.1016\/j.trre.2014.03.002_bb0115","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1111\/j.1600-6143.2010.03129.x","article-title":"Everolimus plus reduced-exposure CsA versus mycophenolic acid plus standard-exposure CsA in renal-transplant recipients","volume":"10","author":"Tedesco Silva","year":"2010","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2014.03.002_bb0120","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1177\/039139880903200608","article-title":"Decreased acute rejection and improved renal allograft survival using sirolimus and low-dose calcineurin inhibitors without induction therapy","volume":"32","author":"Tsai","year":"2009","journal-title":"Int J Artif Organs"},{"key":"10.1016\/j.trre.2014.03.002_bb0125","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1097\/01.TP.0000121504.69676.5E","article-title":"Comparison of sirolimus-based calcineurin inhibitor-sparing and calcineurin inhibitor-free regimens in cadaveric renal transplantation","volume":"77","author":"Lo","year":"2004","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2014.03.002_bb0130","series-title":"Rapamune (sirolimus) oral solution and tablets [prescribing information]","year":"2011"},{"key":"10.1016\/j.trre.2014.03.002_bb0135","series-title":"Zortress (everolimus) tablets for oral use [prescribing information]","year":"2012"},{"key":"10.1016\/j.trre.2014.03.002_bb0140","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/j.1399-0012.2007.00668.x","article-title":"Risk factors for impaired wound healing in sirolimus-treated renal transplant recipients","volume":"21","author":"Knight","year":"2007","journal-title":"Clin Transplant"},{"key":"10.1016\/j.trre.2014.03.002_bb0145","doi-asserted-by":"crossref","first-page":"E625","DOI":"10.1111\/ctr.12223","article-title":"Wound events in kidney transplant patients receiving de novo everolimus: a pooled analysis of three randomized controlled trials","volume":"27","author":"Cooper","year":"2013","journal-title":"Clin Transplant"},{"key":"10.1016\/j.trre.2014.03.002_bb0150","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/j.1600-6143.2012.04334.x","article-title":"The effect of everolimus versus mycophenolate upon proteinuria following kidney transplant and relationship to graft outcomes","volume":"13","author":"Wiseman","year":"2013","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2014.03.002_bb0155","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1399-0012.2010.01232.x","article-title":"mTOR inhibitor-associated dermatologic and mucosal problems","volume":"24","author":"Campistol","year":"2010","journal-title":"Clin Transplant"},{"key":"10.1016\/j.trre.2014.03.002_bb0160","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.oraloncology.2012.11.008","article-title":"A review of oral toxicity associated with mTOR inhibitor therapy in cancer patients","volume":"49","author":"Martins","year":"2013","journal-title":"Oral Oncol"},{"key":"10.1016\/j.trre.2014.03.002_bb0165","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1097\/01.TP.0000056639.74982.F9","article-title":"Oral ulcers in kidney transplant recipients treated with sirolimus and mycophenolate mofetil","volume":"75","author":"van Gelder","year":"2003","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2014.03.002_bb0170","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1188\/09.CJON.S2.19-23","article-title":"Management of mTOR inhibitor side effects","author":"Creel","year":"2009","journal-title":"Clin J Oncol Nurs"},{"key":"10.1016\/j.trre.2014.03.002_bb0175","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.ctrv.2012.12.006","article-title":"A contemporary update on rates and management of toxicities of targeted therapies for metastatic renal cell carcinoma","volume":"39","author":"Alasker","year":"2013","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.trre.2014.03.002_bb0180","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.ejca.2011.02.014","article-title":"Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma","volume":"47","author":"Porta","year":"2011","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.trre.2014.03.002_bb0185","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.oraloncology.2011.08.009","article-title":"Clinical presentation and management of mTOR inhibitor-associated stomatitis","volume":"47","author":"de Oliveira","year":"2011","journal-title":"Oral Oncol"},{"key":"10.1016\/j.trre.2014.03.002_bb0190","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2012.30.15_suppl.e19624","article-title":"Rash to the mTOR inhibitor everolimus: systematic review and meta-analysis","author":"Ramirez-Fort","year":"2012","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.trre.2014.03.002_bb0195","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jaad.2005.11.1072","article-title":"Acne in recipients of renal transplantation treated with sirolimus: clinical, microbiologic, histologic, therapeutic, and pathogenic aspects","volume":"55","author":"Mah\u00e9","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.trre.2014.03.002_bb0200","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1111\/j.1432-2277.2011.01247.x","article-title":"Surgical wound complications after heart transplantation","volume":"24","author":"Zuckermann","year":"2011","journal-title":"Transpl Int"},{"key":"10.1016\/j.trre.2014.03.002_bb0205","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1111\/j.1432-2277.2009.00858.x","article-title":"Practical recommendations for the early use of m-TOR inhibitors (sirolimus) in renal transplantation","volume":"22","author":"Campistol","year":"2009","journal-title":"Transpl Int"},{"key":"10.1016\/j.trre.2014.03.002_bb0210","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1111\/j.1432-2277.2011.01357.x","article-title":"Do wound complications or lymphoceles occur more often in solid organ transplant recipients on mTOR inhibitors? A systematic review of randomized controlled trials","volume":"24","author":"Pengel","year":"2011","journal-title":"Transpl Int"},{"key":"10.1016\/j.trre.2014.03.002_bb0215","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1097\/TP.0b013e318192dd56","article-title":"A systematic approach to minimizing wound problems for de novo sirolimus-treated kidney transplant recipients","volume":"87","author":"Tiong","year":"2009","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2014.03.002_bb0220","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1002\/lt.22445","article-title":"Early use of mammalian target of rapamycin inhibitors is an independent risk factor for incisional hernia development after liver transplantation","volume":"18","author":"Montalti","year":"2012","journal-title":"Liver Transpl"},{"key":"10.1016\/j.trre.2014.03.002_bb0225","doi-asserted-by":"crossref","first-page":"3974","DOI":"10.4049\/jimmunol.181.6.3974","article-title":"Defects in skin \u03b3\u03b4 T cell function contribute to delayed wound repair in rapamycin-treated mice","volume":"181","author":"Mills","year":"2008","journal-title":"J Immunol"},{"key":"10.1016\/j.trre.2014.03.002_bb0230","doi-asserted-by":"crossref","first-page":"e10643","DOI":"10.1371\/journal.pone.0010643","article-title":"Accelerated wound healing by mTOR activation in genetically defined mouse models","volume":"5","author":"Squarize","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.trre.2014.03.002_bb0235","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1016\/j.transproceed.2010.05.162","article-title":"Targeting risk factors for impaired wound healing and wound complications after kidney transplantation","volume":"42","author":"R\u00f8ine","year":"2010","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2014.03.002_bb0240","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1097\/TP.0b013e3181a05b7a","article-title":"Management of side effects of sirolimus therapy","volume":"87","author":"Stallone","year":"2009","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2014.03.002_bb0245","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.trre.2010.01.005","article-title":"Clinical recommendations for the use of everolimus in heart transplantation","volume":"24","author":"Manito","year":"2010","journal-title":"Transplant Rev (Orlando)"},{"key":"10.1016\/j.trre.2014.03.002_bb0250","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1111\/j.1464-410X.2007.07427.x","article-title":"Intraoperative placing of drains decreases the incidence of lymphocele and deep vein thrombosis after renal transplantation","volume":"101","author":"Derweesh","year":"2008","journal-title":"BJU Int"},{"key":"10.1016\/j.trre.2014.03.002_bb0255","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1517\/14740338.2013.752814","article-title":"Adverse events associated with mTOR inhibitors","volume":"12","author":"Pallet","year":"2013","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.trre.2014.03.002_bb0260","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1001\/archsurg.2008.571","article-title":"Laparoscopic incisional hernia repair after solid-organ transplantation","volume":"144","author":"Kennealey","year":"2009","journal-title":"Arch Surg"},{"key":"10.1016\/j.trre.2014.03.002_bb0265","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1007\/s00464-010-1534-8","article-title":"Bacterial clearance of biologic grafts used in hernia repair: an experimental study","volume":"25","author":"Harth","year":"2011","journal-title":"Surg Endosc"},{"key":"10.1016\/j.trre.2014.03.002_bb0270","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s10029-010-0748-y","article-title":"Human acellular dermal matrix for ventral hernia repair reduces morbidity in transplant patients","volume":"15","author":"Brewer","year":"2011","journal-title":"Hernia"},{"key":"10.1016\/j.trre.2014.03.002_bb0275","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1111\/j.1365-2133.2009.09098.x","article-title":"Sirolimus-associated lymphoedema: eight new cases and a proposed mechanism","volume":"160","author":"Desai","year":"2009","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.trre.2014.03.002_bb0280","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1111\/j.1600-6143.2007.02101.x","article-title":"Patient survival and cardiovascular risk after kidney transplantation: the challenge of diabetes","volume":"8","author":"Cosio","year":"2008","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2014.03.002_bb0285","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1111\/j.1600-6143.2007.01749.x","article-title":"Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus","volume":"7","author":"Vincenti","year":"2007","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2014.03.002_bb0290","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1007\/BF03343761","article-title":"The metabolic effects of cyclosporin and tacrolimus","volume":"23","author":"Marchetti","year":"2000","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.trre.2014.03.002_bb0295","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1681\/ASN.2007111202","article-title":"Sirolimus is associated with new-onset diabetes in kidney transplant recipients","volume":"19","author":"Johnston","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.trre.2014.03.002_bb0300","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1111\/j.1600-6143.2004.00389.x","article-title":"Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies","volume":"4","author":"Vitko","year":"2004","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2014.03.002_bb0305","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1016\/j.transproceed.2004.09.026","article-title":"Graft function, cardiovascular risk factors, and sex hormones in renal transplant recipients on an immunosuppressive regimen of everolimus, reduced dose of cyclosporine, and basiliximab","volume":"37","author":"Kr\u00e4mer","year":"2005","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2014.03.002_bb0310","doi-asserted-by":"crossref","first-page":"945","DOI":"10.2337\/db07-0922","article-title":"mTOR inhibition by rapamycin prevents \u03b2-cell adaptation to hyperglycemia and exacerbates the metabolic state in type 2 diabetes","volume":"57","author":"Fraenkel","year":"2008","journal-title":"Diabetes"},{"key":"10.1016\/j.trre.2014.03.002_bb0315","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1200\/JCO.2011.39.7356","article-title":"Management of metabolic effects associated with anticancer agents targeting the PI3K\u2013Akt\u2013mTOR pathway","volume":"30","author":"Busaidy","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.trre.2014.03.002_bb0320","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1007\/s00280-008-0835-2","article-title":"Experiences and practical conclusions concerning temsirolimus use and adverse event management in advanced renal cell carcinoma within a compassionate use program in Germany","volume":"63","author":"Gerullis","year":"2009","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.trre.2014.03.002_bb0325","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1097\/CAD.0b013e32833760bf","article-title":"Emergent toxicities associated with the use of mTOR inhibitors in patients with advanced renal carcinoma","volume":"21","author":"Rodriguez-Pascual","year":"2010","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.trre.2014.03.002_bb0330","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.2337\/dc12-0413","article-title":"Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"35","author":"Inzucchi","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.trre.2014.03.002_bb0335","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1111\/j.1399-0012.2007.00686.x","article-title":"Comparison of sirolimus and everolimus in their effects on blood lipid profiles and haematological parameters in heart transplant recipients","volume":"21","author":"Tenderich","year":"2007","journal-title":"Clin Transplant"},{"key":"10.1016\/j.trre.2014.03.002_bb0340","author":"National Cholesterol Education Program"},{"key":"10.1016\/j.trre.2014.03.002_bb0345","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/j.1600-6135.2004.0355.x","article-title":"Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: a report from the Managing Dyslipidemias in Chronic Kidney Disease Work Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative","volume":"4","author":"Kasiske","year":"2004","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2014.03.002_bb0350","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1053\/j.ajkd.2009.06.031","article-title":"Proteinuria in kidney transplant recipients: prevalence, prognosis, and evidence-based management","volume":"54","author":"Knoll","year":"2009","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.trre.2014.03.002_bb0355","first-page":"404","article-title":"Causes and consequences of proteinuria following kidney transplantation","volume":"31","author":"Su\u00e1rez Fern\u00e1ndez","year":"2011","journal-title":"Nefrologia"},{"key":"10.1016\/j.trre.2014.03.002_bb0360","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1016\/j.transproceed.2011.06.045","article-title":"Is proteinuria reversible, after withdrawal of mammalian target of rapamycin inhibitors?","volume":"43","author":"Arnau","year":"2011","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2014.03.002_bb0365","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.trre.2007.12.001","article-title":"mToR inhibitors-induced proteinuria: mechanisms, significance, and management","volume":"22","author":"Letavernier","year":"2008","journal-title":"Transplant Rev (Orlando)"},{"key":"10.1016\/j.trre.2014.03.002_bb0370","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1097\/01.tp.0000228921.43200.f7","article-title":"Differences in proteinuria and graft function in de novo sirolimus-based vs. calcineurin inhibitor-based immunosuppression in live donor kidney transplantation","volume":"82","author":"Stephany","year":"2006","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2014.03.002_bb0375","doi-asserted-by":"crossref","first-page":"F569","DOI":"10.1152\/ajprenal.00180.2012","article-title":"The mTOR-inhibitor rapamycin mediates proteinuria in nephrotoxic serum nephritis by activating the innate immune response","volume":"303","author":"Kirsch","year":"2012","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.trre.2014.03.002_bb0380","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.trre.2011.10.003","article-title":"mTOR inhibitor-associated proteinuria in kidney transplant recipients","volume":"26","author":"Diekmann","year":"2012","journal-title":"Transplant Rev (Orlando)"},{"key":"10.1016\/j.trre.2014.03.002_bb0385","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1097\/TP.0b013e318211d342","article-title":"Sirolimus and proteinuria in renal transplant patients: evidence for a dose-dependent effect on slit diaphragm-associated proteins","volume":"91","author":"Stallone","year":"2011","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2014.03.002_bb0390","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1021\/tx800253x","article-title":"Urine metabolites reflect time-dependent effects of cyclosporine and sirolimus on rat kidney function","volume":"22","author":"Klawitter","year":"2009","journal-title":"Chem Res Toxicol"},{"key":"10.1016\/j.trre.2014.03.002_bb0395","doi-asserted-by":"crossref","first-page":"e48063","DOI":"10.1371\/journal.pone.0048063","article-title":"Everolimus and sirolimus in combination with cyclosporine have different effects on renal metabolism in the rat","volume":"7","author":"Bohra","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.trre.2014.03.002_bb0400","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1517\/14740338.2012.722993","article-title":"A drug safety evaluation of everolimus in kidney transplantation","volume":"11","author":"Holdaas","year":"2012","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.trre.2014.03.002_bb0405","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1097\/00007890-199608150-00002","article-title":"Synergistic effects of cyclosporine and rapamycin in a chronic nephrotoxicity model","volume":"62","author":"Andoh","year":"1996","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2014.03.002_bb0410","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1038\/sj.bjp.0705939","article-title":"Alterations in glucose metabolism by cyclosporine in rat brain slices link to oxidative stress: interactions with mTOR inhibitors","volume":"143","author":"Christians","year":"2004","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.trre.2014.03.002_bb0415","first-page":"475-475","article-title":"North\/South American, double-blind, parallel group study of the safety and efficacy of Certican\u2122 (RAD) versus mycophenolate mofetil (MMF) in combination with Neoral\u00ae and corticosteroids","volume":"1","author":"Kaplan","year":"2001","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2014.03.002_bb0420","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/ctr.12045","article-title":"Association of clinical events with everolimus exposure in kidney transplant patients receiving reduced cyclosporine","volume":"27","author":"Shihab","year":"2013","journal-title":"Clin Transplant"},{"key":"10.1016\/j.trre.2014.03.002_bb0425","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1034\/j.1600-6143.2003.00078.x","article-title":"Sirolimus prolongs recovery from delayed graft function after cadaveric renal transplantation","volume":"3","author":"McTaggart","year":"2003","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2014.03.002_bb0430","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/j.1600-6143.2008.02477.x","article-title":"The detrimental effect of poor early graft function after laparoscopic live donor nephrectomy on graft outcomes","volume":"9","author":"Nogueira","year":"2009","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2014.03.002_bb0435","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1111\/j.1432-2277.2010.01094.x","article-title":"Efficacy and safety of de novo or early everolimus with low cyclosporine in deceased-donor kidney transplant recipients at specified risk of delayed graft function: 12-month results of a randomized, multicenter trial","volume":"23","author":"Dantal","year":"2010","journal-title":"Transpl Int"},{"key":"10.1016\/j.trre.2014.03.002_bb0440","doi-asserted-by":"crossref","first-page":"F180","DOI":"10.1152\/ajprenal.00015.2012","article-title":"Mammalian target of rapamycin and the kidney. II. Pathophysiology and therapeutic implications","volume":"303","author":"Lieberthal","year":"2012","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.trre.2014.03.002_bb0445","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1164\/rccm.200911-1720OC","article-title":"Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma","volume":"182","author":"White","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.trre.2014.03.002_bb0450","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1097\/01.TP.0000118413.92211.B6","article-title":"Sirolimus-associated pulmonary toxicity","volume":"77","author":"Pham","year":"2004","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2014.03.002_bb0455","first-page":"166","article-title":"Interstitial pneumonitis in the transplant patient: consider sirolimus-associated pulmonary toxicity","volume":"161","author":"Feagans","year":"2009","journal-title":"J La State Med Soc"},{"key":"10.1016\/j.trre.2014.03.002_bb0460","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.1093\/ndt\/gfn401","article-title":"Severe everolimus-associated pneumonitis in a renal transplant recipient","volume":"23","author":"Alexandru","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.trre.2014.03.002_bb0465","doi-asserted-by":"crossref","first-page":"2792","DOI":"10.1016\/j.transproceed.2011.06.060","article-title":"Sirolimus-induced pneumonitis complicated by pentamidine-induced phospholipidosis in a renal transplant recipient: a case report","volume":"43","author":"Filippone","year":"2011","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2014.03.002_bb0470","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1038\/ki.2009.231","article-title":"Posttransplant anemia: the role of sirolimus","volume":"76","author":"Fishbane","year":"2009","journal-title":"Kidney Int"},{"key":"10.1016\/j.trre.2014.03.002_bb0475","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1016\/j.transproceed.2007.06.032","article-title":"Study of anemia after late introduction of everolimus in the immunosuppressive treatment of renal transplant patients","volume":"39","author":"S\u00e1nchez Fructuoso","year":"2007","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2014.03.002_bb0480","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1016\/j.transproceed.2010.05.158","article-title":"Sirolimus is associated with impaired hematopoiesis in heart transplant patients? A retrospective analysis","volume":"42","author":"McDonald","year":"2010","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2014.03.002_bb0485","doi-asserted-by":"crossref","first-page":"3821","DOI":"10.1016\/j.transproceed.2005.10.054","article-title":"Prevalence of anemia in renal transplant patients: results from MOST, an observational trial","volume":"37","author":"Fern\u00e1ndez Fresnedo","year":"2005","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2014.03.002_bb0490","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1093\/ndt\/gfr318","article-title":"mTOR inhibition and erythropoiesis: microcytosis or anaemia?","volume":"27","author":"Diekmann","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.trre.2014.03.002_bb0495","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1097\/TP.0b013e318200e971","article-title":"Genetic determinants of mycophenolate-related anemia and leukopenia after transplantation","volume":"91","author":"Jacobson","year":"2011","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2014.03.002_bb0500","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1097\/00007890-200005270-00019","article-title":"Sirolimus-induced thrombocytopenia and leukopenia in renal transplant recipients: risk factors, incidence, progression, and management","volume":"69","author":"Hong","year":"2000","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2014.03.002_bb0505","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/j.1432-2277.2010.01140.x","article-title":"Calcineurin inhibitor sparing regimens using m-target of rapamycin inhibitors: an opportunity to improve cardiovascular risk following kidney transplantation?","volume":"24","author":"Zeier","year":"2011","journal-title":"Transpl Int"},{"key":"10.1016\/j.trre.2014.03.002_bb0510","doi-asserted-by":"crossref","first-page":"703","DOI":"10.2215\/CJN.07371009","article-title":"Increased incidence of angioedema with ACE inhibitors in combination with mTOR inhibitors in kidney transplant recipients","volume":"5","author":"Duerr","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.trre.2014.03.002_bb0515","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1097\/TP.0b013e31824bf1f0","article-title":"Sirolimus-associated testicular toxicity: detrimental but reversible","volume":"93","author":"Rovira","year":"2012","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2014.03.002_bb0520","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1046\/j.1600-6135.2003.00279.x","article-title":"Testosterone concentrations and sirolimus in male renal transplant patients","volume":"4","author":"Fritsche","year":"2004","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2014.03.002_bb0525","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/j.1432-2277.2006.00423.x","article-title":"Gonadal impact of target of rapamycin inhibitors (sirolimus and everolimus) in male patients: an overview","volume":"20","author":"Huyghe","year":"2007","journal-title":"Transpl Int"},{"key":"10.1016\/j.trre.2014.03.002_bb0530","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1111\/j.1432-2277.2009.00839.x","article-title":"High prevalence of ovarian cysts in premenopausal women receiving sirolimus and tacrolimus after clinical islet transplantation","volume":"22","author":"Alfadhli","year":"2009","journal-title":"Transpl Int"},{"key":"10.1016\/j.trre.2014.03.002_bb0535","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1097\/01.TP.0000147301.41864.C0","article-title":"Alterations of the female reproductive system in recipients of islet grafts","volume":"78","author":"Cure","year":"2004","journal-title":"Transplantation"}],"container-title":["Transplantation Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0955470X14000238?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0955470X14000238?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T21:19:59Z","timestamp":1716585599000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0955470X14000238"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7]]},"references-count":107,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,7]]}},"alternative-id":["S0955470X14000238"],"URL":"https:\/\/doi.org\/10.1016\/j.trre.2014.03.002","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.727917555.793546420","asserted-by":"object"}]},"ISSN":["0955-470X"],"issn-type":[{"value":"0955-470X","type":"print"}],"subject":[],"published":{"date-parts":[[2014,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Strategies for the management of adverse events associated with mTOR inhibitors","name":"articletitle","label":"Article Title"},{"value":"Transplantation Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trre.2014.03.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}